Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin)

Inclusion Criteria:

* Diagnosis of locally advanced or metastatic colorectal cancer.
* No prior chemotherapy for metastatic disease.
* Presence of radiologically and/or clinically documented disease.
* Eastern Cooperative Oncology Group performance status of 0 or 1.
* Adequate bone marrow, hepatic, renal function, Urine Creatinine Ratio (UPC) of \<
* A female subject must not be pregnant or breast feeding.
* Able to swallow and retain oral medications.

Exclusion Criteria:

* Has had any major surgery, chemotherapy, hormone therapy, investigational agent, or radiotherapy within the last 28 days
* Prior treatment with pazopanib, or oxaliplatin.
* Known contraindications to the use of oxaliplatin, capecitabine, 5-fluorouracil, or folinic acid.
* Participation in any investigational study within 28 days prior to study treatment.
* Women who are pregnant or lactating.
* Poorly controlled hypertension.
* A history of cardiovascular disease, arrhythmias, or significant ECG abnormalities.
* Any history of stroke.
* Current use of therapeutic warfarin.
* Known brain metastases.
* History of disease significantly affecting gastrointestinal function or major resection of the stomach or small bowel.
* Active infections or other serious illness.
* History of allergy to platinum compounds or heparin.
* Poor venous access.